Clinical Trials Browser

durvalumab × Other solid neoplasm × Clear all

NCT04999969 2026-04-30

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

Phase 2 Active not recruiting

126 enrolled 30 charts

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumours

NCT05514132 2026-03-09

A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours

Phase 1 Active not recruiting

Other solid neoplasm

Advanced Solid Tumours

NCT02617277 2026-03-04

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumours

NCT02499328 2026-02-11

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Phase 1/2 Completed

340 enrolled 53 charts

Head & NeckOther solid neoplasm

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT04334759 2026-01-22

DREAM3R

Phase 3 Completed

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT06302426 2026-01-16

Trial of INI-4001 in Patients With Advanced Solid Tumours

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT03075527 2026-01-08

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Phase 2 Terminated

19 enrolled 12 charts

Other solid neoplasmThoracic

Mesothelioma

NCT05380713 2025-12-29

......SMARTEST Trial......

Phase 2 Completed

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05932199 2025-09-25

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Phase 1/2 Recruiting

Other solid neoplasmThoracic

Mesothelioma

NCT04613492 2025-06-24

A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumors

NCT03421353 2024-08-21

AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumours

NCT02301130 2024-04-25

Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumors

NCT02718911 2023-10-16

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

Phase 1 Completed

72 enrolled 23 charts

Other solid neoplasm

Solid Tumor

NCT02899195 2023-07-05

PrE0505

Phase 2 Completed

55 enrolled 13 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT04115111 2023-03-15

Diadem

Phase 2 Completed

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT03889275 2023-02-21

A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumors

NCT02592551 2022-09-29

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

Phase 2 Completed

24 enrolled 22 charts

Other solid neoplasmThoracic

Mesothelioma

NCT04261075 2022-08-15

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumors

NCT03665129 2022-01-27

STELLAR-001

Phase 1 Terminated

Other solid neoplasm

Advanced Solid Tumors

NCT01693562 2021-05-13

A Phase 1/2 Study to Evaluate MEDI4736

Phase 1/2 Completed

1,022 enrolled 42 charts

Other solid neoplasm

Advanced Solid Tumors

NCT02900157 2021-01-14

Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumors

NCT03089645 2020-07-27

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumors

NCT02261220 2020-03-06

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumors

NCT02737072 2019-08-12

A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

Phase 1 Terminated

9 enrolled 13 charts

Other solid neoplasm

Solid Tumor

NCT02141347 2018-12-12

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Phase 1 Completed

Other solid neoplasmThoracic

Part A and B: Advanced Solid Malignancies

NCT02588131 2015-10-27

A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma, Malignant